InVivo Plus Recombinant CTLA-4-Ig (hum/hum) (HB651031)

Name: InVivo Plus Recombinant CTLA-4-Ig (hum/hum)
Brand: abinScience
SKU: HB651031
Price: 298 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

50ug
100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB651031
Description	InVivo Plus Recombinant CTLA-4-Ig (hum/hum) (HB651031) expressed in Mammalian Cells. Purity: >90% as determined by SDS-PAGE. by SDS-PAGE. Highlights ●Recombinant — Consistent lot-to-lot performance. ●High Purity — >90% as determined by SDS-PAGE. by SDS-PAGE for demanding downstream applications.
Applications	ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Clonality	Monoclonal
Species	Homo sapiens (Human)
Nature	Recombinant
Target	HA, Hemagglutinin, Hemagglutinin HA1 chain, Hemagglutinin HA2 chain
Endotoxin level	< 1 EU/mg as determined by LAL method.
Purity	>95% as determined by SDS-PAGE.
Associated products	pH 7.4 Dilution Buffer
Purification	Protein A/G purified from cell culture supernatant.
Accession	P16410
Form	Lyophilized
Storage buffer	Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Reconstitution	Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping	In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	CD152, CTLA-4, CTLA4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
Background	Cytotoxic T-lymphocyte protein 4 (CD152/CTLA4) is a ~24 kDa protein. Inhibitory receptor acting as a major negative regulator of T-cell responses. Acts as a decoy receptor: the affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28. CD152 is the therapeutic target of ipilimumab (Yervoy). 1. Schwartz, JC. et al. (2001) Nature 410, 604-8. PMID: 11279501 2. Stamper, CC. et al. (2001) Nature 410, 608-11. PMID: 11279502 3. Teft, WA. et al. (2006) Annual review of immunology 24, 65-97. PMID: 16551244 4. Linsley, PS. et al. (1991) The Journal of experimental medicine 174, 561-9. PMID: 1714933 5. Zheng, Y. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 1683-91. PMID: 18641304 6. Ramagopal, UA. et al. (2017) Proceedings of the National Academy of Sciences of the United States of America 114, E4223-E4232. PMID: 28484017
Note	For research use only